Sepsis is a dysregulated host response to infection that leads to life-threatening organ dysfunction and represents a major healthcare problem. Septic shock is the most severe form, characterized by increased capillary permeability and vasodilation, resulting in hypotension and tissue hypoxia. Early identification and treatment of tissue hypoperfusion are pivotal components of initial resuscitation to limit progression to multiple organ dysfunction and death. The 2021 Surviving Sepsis Guidelines recommend guiding initial resuscitation by targeting decreases in serum lactate levels in patients with elevated lactate. However, although elevated lactate levels may reflect tissue hypoxia, serum lactate is not a direct marker of tissue perfusion. Hyperlactatemia may be attributable to mechanisms other than tissue hypoperfusion, such as accelerated aerobic glycolysis driven by excessive β-adrenergic stimulation or impaired clearance (e.g., in liver failure). The venous-to-arterial carbon dioxide partial pressure difference (CO₂ gap), which is inversely related to cardiac output, has been shown to reflect the adequacy of venous blood flow to remove CO₂ from tissues. The CO₂ gap is closely linked to microcirculatory blood flow during the early resuscitation phase of septic shock and may effectively identify persistent tissue hypoperfusion in shock states. A persistently high CO₂ gap during early resuscitation has been associated with significantly higher 28-day mortality and increased Sequential Organ Failure Assessment (SOFA) scores. Moreover, the CO₂ gap has been shown to respond to changes in cardiac output during inotrope infusion in patients with low blood flow, suggesting that its assessment could be useful for therapeutic adjustments. Therefore, there are compelling arguments to evaluate the usefulness of the CO₂ gap in guiding early resuscitation in patients with septic shock. The investigators postulated that CO₂ gap-guided early resuscitation may be more effective in improving outcomes than lactate-guided resuscitation.
Main objective: The aim of the CARBON trial is to compare a veno-arterial CO2 difference-guided resuscitation strategy (CO2gap-guided strategy) with a lactate level-guided resuscitation on mortality in adults intensive care unit (ICU) patients fulfilling the SEPSIS-3 criteria consensus definition. HYPOTHESIS: The investigators hypothesized that a CO2gap-guided resuscitation strategy during early septic shock would reduce mortality compared with a lactate level-guided resuscitation.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
750
For patients assigned to the interventional arm, adherence to the algorithm will complement clinical practices in the following areas: * Blood sampling for venous blood gas analysis. Blood samples will be taken from an existing central venous catheter; central venous access is common clinical practice in critically ill patients. * The use of dobutamine and blood transfusions in patients showing signs of oxygen deficiency (both will be carried out in accordance with the intended use and conditions of current practice).
CHU Clermont-Ferrand Estaing
Clermont-Ferrand, France
CHU Clermont-Ferrand Gabriel Montpied
Clermont-Ferrand, France
The primary end point is all-cause mortality at 28 days after randomization
Time frame: Every day until Day 28
Key secondary endpoints
Duration of septic shock (i.e., vasopressor use) up to Day 28
Time frame: Every day until Day 28
Key secondary endpoints
All-cause mortality at Day 90
Time frame: Every day until Day 90
Secondary Efficacy Endpoints
Vasopressor-free and inotrope-free days up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Renal replacement therapy-free days (excluding patients on renal replacement therapy at time of randomization) up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Mechanical ventilation-free days up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Duration of renal replacement therapy (excluding patients on renal replacement therapy at time of randomization) up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Duration of mechanical ventilation up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Incidence of new organ dysfunction (based on the SOFA score) up to Day 7
Time frame: Every day until Day 7
Secondary Efficacy Endpoints
ICU-free days up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
ICU length of stay up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Hospital length of stay up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
EuroQol 5 Dimensions, 5 Levels (EQ-5D-5L) :a measure of health-related quality of life at Day 90: The EQ-5D-5L score is analyzed using the utility value (global index score). In France, the score ranges from about -0.53 (health states considered worse than death) to 1.00 (full health). 0.00 corresponds to a health state equivalent to death.
Time frame: At Day 90 after randomization
Secondary Safety Endpoints
Incidence of adverse events with specific emphasis on the incidence of ischemic (e.g., myocardial, stroke, intestinal, limb ischemia) and arrhythmia (excluding sinus tachycardia or sinus arrhythmia) events reported as having a reasonable possibility of a causal relationship with the study procedures
Time frame: Every day until Day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.